WAS and Down syndrome: The lack of a transcriptionally active long-terminal repeat of the self-inactivating lentiviral backbone, combined with a moderately active internal promoter to drive transgene expression, such as the WASP endogenous promoter, is a major safety advantage of the vector compared with the γ-retroviral vector used in the German Wiskott-Aldrich syndrome study.11